Serial BNP Sampling Does Not Improve Prognostic Value

Baseline levels in patients with chest pain best predictor of late adverse events

THURSDAY, March 15 (HealthDay News) -- While baseline brain natriuretic peptide (BNP) levels can predict adverse events up to three months after a patient presents with chest pain, serial sampling does not improve the test's predictive value, according to a report in the March 20 issue of the Journal of the American College of Cardiology.

Robert Fitzgerald, Ph.D., from the University of California, San Diego, and colleagues studied 276 patients presenting to the emergency department for chest pain who were followed-up for 90 days. In the first 24 hours after arrival at the hospital, the researchers measured BNP and amino-terminal (NT)-proBNP up to five times.

The investigators found that natriuretic peptides were diagnostic for congestive heart failure and new-onset congestive heart failure but less so for acute coronary syndromes. Baseline measurements were predictive of levels measured up to 12 hours later and did not improve the predictive value of the test.

"In this relatively small single-site study, the prognostic value of natriuretic peptides was in the assessment of baseline concentrations, and not in short-term monitoring for changing levels," the authors write.

This study was supported by Roche Diagnostics, Biosite Diagnostics, and Bayer Diagnostics. One author is a consultant for Biosite.

Full Text (subscription or payment may be required)

Physician's Briefing